On July 23, 2026, Eli Lilly and Co (NYSE: LLY) announced promising top-line data from its Phase 3 studies, TRIUMPH-2 and TRIUMPH-3, focused on retatrutide, a pioneering triple hormone receptor agonist
The primary outcome was the new onset of adverse CVEs, including heart failure, composite incidence of major adverse cardiovascular events (MACE
When to be concerned: New-onset central vision distortion (e.g., wavy lines, difficulty reading, dark blur in central vision), especially in older patients
Apoyo al metabolismo de grasas: Al facilitar su uso como energa, puede contribuir a una reduccin en el porcentaje de grasa corporal cuando se combina con ejercicio y dieta adecuados
It can also be used to save on longer 56-day and 84-day refills, but the 13-box limit still applies
& Harmatz, J